High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both in Vitro Protease Activity and Late Events of Viral Replication

Molecular Therapy Nucleic Acids

Volumn 4, Issue 2, 2015, Pages e228-

  Duclair, Sonald ^a   Gautam, Archana ^a   Ellington, Andrew ^b   Prasad, Vinayaka R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

anti HIV 1 gene therapy; HIV 1 inhibitor; HIV 1 PR inhibitor; RNA aptamer; RNA aptamer structure

Indexed keywords

APTAMER; ASPARTIC PROTEINASE; CATHEPSIN D; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NUCLEOTIDE; PROTEINASE INHIBITOR; RNA;

3' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84927949432     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.1     Document Type: Article

References (63)

1. Gottlinger, HG, Sodroski, JG and Haseltine, WA (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type-1. Proc Natl Acad Sci USA 86: 5781-5785.
2. Seelmeier, S, Schmidt, H, Turk, V and Vonderhelm, K (1988). Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin-A. Proc Natl Acad Sci USA 85: 6612-6616.
3. Wiegers, K, Rutter, G, Kottler, H, Tessmer, U, Hohenberg, H and Kräusslich, HG (1998). Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 72: 2846-2854.
4. Kaplan, AH, Manchester, M and Swanstrom, R (1994). The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 68: 6782-6786.
5. McQuade, TJ, Tomasselli, AG, Liu, L, Karacostas, V, Moss, B, Sawyer, TK et al. (1990). A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247: 454-456.
6. Schätzl, H, Gelderblom, HR, Nitschko, H and von der Helm, K (1991). Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor. Arch Virol 120: 71-81.
7. Wlodawer, A and Vondrasek, J (1998). Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 27: 249-284.
8. Vacca, JP and Condra, JH (1997). Clinically effective HIV-1 protease inhibitors. Drug Discov Today 2: 261-272.
9. Palella, FJ Jr, Delaney, KM, Moorman, AC, Loveless, MO, Fuhrer, J, Satten, GA et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
10. Hammer, SM, Katzenstein, DA, Hughes, MD, Gundacker, H, Schooley, RT, Haubrich, RH et al. (1996). A trial comparing nucleoside monotherapy with combination therapy in HIVinfected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335: 1081-1090.
11. Hoetelmans, RM, Meenhorst, PL, Mulder, JW, Burger, DM, Koks, CH and Beijnen, JH (1997). Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 19: 159-175.
12. Weber, IT (1990). Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J Biol Chem 265: 10492-10496.
13. Gustchina, A and Weber, IT (1991). Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10: 325-339.
14. Boggetto, N and Reboud-Ravaux, M (2002). Dimerization inhibitors of HIV-1 protease. Biol Chem 383: 1321-1324.
15. Zhang, ZY, Poorman, RA, Maggiora, LL, Heinrikson, RL and Kézdy, FJ (1991). Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 266: 15591-15594.
16. Schramm, HJ, de Rosny, E, Reboud-Ravaux, M, Büttner, J, Dick, A and Schramm, W (1999). Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol Chem 380: 593-596.
17. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
18. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
19. Somasunderam, A, Ferguson, MR, Rojo, DR, Thiviyanathan, V, Li, X, O'Brien, WA et al. (2005). Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 44: 10388-10395.
20. Tuerk, C, Macdougal, S and Gold, L (1992). RNA pseudoknots that inhibit human-immunodeficiency-virus type-1 reverse-transcriptase. Proc Natl Acad Sci USA 89: 6988-6992.
21. Allen, P, Worland, S and Gold, L (1995). Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology 209: 327-336.
22. Yamamoto, R, Toyoda, S, Viljanen, P, Machida, K, Nishikawa, S, Murakami, K et al. (1995). In vitro selection of RNA aptamers that can bind specifically to Tat protein of HIV-1. Nucleic Acids Symp Ser 34: 145-146.
23. Duconge, F and Toulme, JJ (1999). In vitro selection identifies key determinants for looploop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA-Publ RNA Soc 5: 1605-1614.
24. Giver, L, Bartel, D, Zapp, M, Pawul, A, Green, M and Ellington, AD (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic Acids Res 21: 5509-5516.
25. Jensen, KB, Atkinson, BL, Willis, MC, Koch, TH and Gold, L (1995). Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands. Proc Natl Acad Sci USA 92: 12220-12224.
26. Ramalingam, D, Duclair, S, Datta, SA, Ellington, A, Rein, A and Prasad, VR (2011). RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol 85: 305-314.
27. Lochrie, MA, Waugh, S, Pratt, DG Jr, Clever, J, Parslow, TG and Polisky, B (1997). In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein. Nucleic Acids Res 25: 2902-2910.
28. Kim, SJ, Kim, MY, Lee, JH, You, JC and Jeong, S (2002). Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem Biophys Res Commun 291: 925-931.
29. Sayer, N, Ibrahim, J, Turner, K, Tahiri-Alaoui, A and James, W (2002). Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem Biophys Res Commun 293: 924-931.
30. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
31. Sekiya, S, Nishikawa, F, Fukuda, K and Nishikawa, S (2003). Structure/function analysis of an RNA aptamer for hepatitis C virus NS3 protease. J Biochem 133: 351-359.
32. Povsic, TJ, Vavalle, JP, Alexander, JH, Aberle, LH, Zelenkofske, SL, Becker, RC et al.; RADAR Investigators. (2014). Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention 10: 431-438.
33. Joshi, P and Prasad, VR (2002). Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 76: 6545-6557.
34. Chaloin, L, Lehmann, MJ, Sczakiel, G and Restle, T (2002). Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 30: 4001-4008.
35. Joshi, PJ, North, TW and Prasad, VR (2005). Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication. Mol Ther 11: 677-686.
36. Kolb, G, Reigadas, S, Castanotto, D, Faure, A, Ventura, M, Rossi, JJ et al. (2006). Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication. RNA Biol 3: 150-156.
37. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H et al. (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66ra6.
38. Lange, MJ, Sharma, TK, Whatley, AS, Landon, LA, Tempesta, MA, Johnson, MC et al. (2012). Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing. Mol Ther 20: 2304-2314.
39. Rossi, JJ, June, CH and Kohn, DB (2007). Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
40. Kitchen, SG, Shimizu, S and An, DS (2011). Stem cell-based anti-HIV gene therapy. Virology 411: 260-272.
41. Mitsuyasu, RT, Merigan, TC, Carr, A, Zack, JA, Winters, MA, Workman, C et al. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
42. Morgan, RA, Walker, R, Carter, CS, Natarajan, V, Tavel, JA, Bechtel, C et al. (2005). Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16: 1065-1074.
43. Levine, BL, Humeau, LM, Boyer, J, MacGregor, RR, Rebello, T, Lu, X et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377.
44. Tebas, P, Stein, D, Tang, WW, Frank, I, Wang, SQ, Lee, G et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-910.
45. Li, N, Wang, YX, Pothukuchy, A, Syrett, A, Husain, N, Gopalakrisha, S et al. (2009). Aptamers that recognize drug-resistant HIV-1 reverse transcriptase (vol 36, pg 6739, 2008). Nucleic Acids Res 37: 5236-5236.
46. Zuker, M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
47. Liaudet-Coopman, E, Beaujouin, M, Derocq, D, Garcia, M, Glondu-Lassis, M, Laurent- Matha, V et al. (2006). Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 237: 167-179.
48. He, J, Choe, S, Walker, R, Di Marzio, P, Morgan, DO and Landau, NR (1995). Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
49. Scherer, LJ, Frank, R and Rossi, JJ (2007). Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res 35: 2620-2628.
50. Lee, NS, Dohjima, T, Bauer, G, Li, H, Li, MJ, Ehsani, A et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505.
51. Perryman, AL, Lin, JH and McCammon, JA (2004). HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs (vol 13, pg 1108, 2004). Protein Sci 13: 1434-1434.
52. Hornak, V and Simmerling, C (2007). Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today 12: 132-138.
53. Navia, MA, Fitzgerald, PM, McKeever, BM, Leu, CT, Heimbach, JC, Herber, WK et al. (1989). Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337: 615-620.
54. Wlodawer, A, Miller, M, Jaskólski, M, Sathyanarayana, BK, Baldwin, E, Weber, IT et al. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245: 616-621.
55. Vondrasek, J and Wlodawer, A (2002). HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins 49: 429-431.
56. Nicholson, LK, Yamazaki, T, Torchia, DA, Grzesiek, S, Bax, A, Stahl, SJ et al. (1995). Flexibility and function in HIV-1 protease. Nat Struct Biol 2: 274-280.
57. Freedberg, DI, Ishima, R, Jacob, J, Wang, YX, Kustanovich, I, Louis, JM et al. (2002). Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci 11: 221-232.
58. Ishima, R, Freedberg, DI, Wang, YX, Louis, JM and Torchia, DA (1999). Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 7: 1047-1055.
59. Bowman, MJ, Byrne, S and Chmielewski, J (2005). Switching between allosteric and dimerization inhibition of HIV-1 protease. Chem Biol 12: 439-444.
60. Rezacova, P, Brynda, J, Lescar, J, Fabry, M, Horejsi, M, Sieglova, I et al. (2005). Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide. J Struct Biol 149: 332-337.
61. Huang, L, Sayer, JM, Swinford, M, Louis, JM and Chen, C (2009). Modulation of human immunodeficiency virus type 1 protease autoprocessing by charge properties of surface residue 69. J Virol 83: 7789-7793.
62. Piasecki, SK, Hall, B and Ellington, AD (2009). Nucleic acid pool preparation and characterization. Methods Mol Biol 535: 3-18.
63. Connor, RI, Chen, BK, Choe, S and Landau, NR (1995). Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944.